BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity awards approved March 18, 2026 for 29 new employees totaling 70,916 restricted stock units.

One-fourth of each award vests on February 16, 2027, then one-twelfth of the remainder vests quarterly thereafter, subject to continued employment. Awards were granted under the company Plan adopted November 2019 and amended February 10, 2023 and December 13, 2023, pursuant to Nasdaq Listing Rule 5635(c)(4).

Key Figures

New employees: 29 employees Inducement RSUs: 70,916 shares Initial vesting date: February 16, 2027 +5 more

8 metrics

New employees 29 employees Recipients of inducement equity grants on March 18, 2026

Inducement RSUs 70,916 shares Aggregate restricted stock units granted as inducement awards

Initial vesting date February 16, 2027 One-fourth of RSU shares vest on this date

Initial vesting portion One-fourth First tranche of each employee’s RSU award

Subsequent vesting fraction One-twelfth Quarterly vesting of remaining RSU shares after initial cliff

Plan adoption November 2019 Equity plan originally adopted by board

Plan amendment date February 10, 2023 First amendment and restatement of the Plan

Plan amendment date December 13, 2023 Second amendment and restatement of the Plan

Market Reality Check

Price: $70.10 Vol: Volume 877,162 is 0.33x t...

low vol

$70.10 Last Close

Volume Volume 877,162 is 0.33x the 20-day average of 2,696,095, indicating subdued trading ahead of this filing-type news. low

Technical Shares trade above the 200-day MA of 59.79 at a price of 70.10, reflecting a longer-term uptrend into this announcement.

Peers on Argus

BBIO slipped 0.07% with light volume, while key peers were mixed: BMRN -0.76%, I...

1 Up

BBIO slipped 0.07% with light volume, while key peers were mixed: BMRN -0.76%, IONS -0.11%, EXEL +0.78%, ASND -1.89%, SMMT +2.14%. Only IONS appeared in momentum scans, suggesting stock-specific trading rather than a sector-driven move.

Historical Context

5 past events · Latest: Mar 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 11	Phase 3 efficacy data	Positive	-3.9%	Positive Phase 3 FORTIFY interim efficacy and safety data for BBP-418.
Mar 04	Clinical data update	Positive	+3.1%	Announcement of additional Phase 3 FORTIFY data presentations at MDA conference.
Feb 24	Earnings and pipeline	Positive	-2.6%	Q4 and FY 2025 results with strong revenue and multiple positive Phase 3 readouts.
Feb 23	Investor conferences	Neutral	-0.3%	Participation in three March 2026 healthcare investor conferences and webcasts.
Feb 17	Inducement equity grants	Neutral	-2.5%	Inducement RSU grants to 34 new employees under Nasdaq Rule 5635(c)(4).

Pattern Detected

Recent positive clinical and earnings updates have twice been followed by negative next-day moves, while more routine news (conferences, inducement grants) also saw mild pressure, suggesting a tendency for shares to consolidate or fade after good headlines.

Recent Company History

Over the last month, BridgeBio reported multiple catalysts. On Feb 24, Q4 and full-year 2025 results highlighted $154.2M quarterly and $502.1M annual revenue plus major pipeline progress, yet shares fell 2.59%. Positive Phase 3 FORTIFY data on Mar 11 drove a 3.11% gain, but another favorable interim update on Mar 11 saw a 3.94% decline. Routine conference participation and prior inducement grants in February drew small negative reactions, framing today’s inducement grants as part of ongoing hiring and equity compensation activity.

Market Pulse Summary

This announcement details inducement RSU grants covering 70,916 shares for 29 new employees under Na...

Analysis

This announcement details inducement RSU grants covering 70,916 shares for 29 new employees under Nasdaq Listing Rule 5635(c)(4), with a vesting schedule beginning on February 16, 2027. It follows similar grants disclosed on Feb 17, 2026 and occurs against a backdrop of recent clinical, earnings, and insider-trading filings. Investors may watch future disclosures around equity compensation, insider transactions, and pipeline milestones to contextualize any dilution and alignment of incentives.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"approved equity grants to 29 new employees in restricted stock units for an aggregate..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)..."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

PALO ALTO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on March 18, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 29 new employees in restricted stock units for an aggregate of 70,916 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on February 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com    
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

What did BridgeBio (BBIO) disclose about the March 18, 2026 inducement grants?

BridgeBio granted 70,916 restricted stock units to 29 new employees as inducements. According to the company, awards were approved March 18, 2026 and issued under the existing Plan in line with Nasdaq Listing Rule 5635(c)(4).

How does the BBIO RSU vesting schedule work for the March 2026 hires?

One-fourth of each RSU grant vests on February 16, 2027, then remaining shares vest quarterly at one-twelfth. According to the company, vesting is subject to continued employment with BridgeBio or its subsidiaries on each vesting date.

How many employees received inducement awards from BridgeBio (BBIO) in March 2026?

A total of 29 new employees received inducement restricted stock unit awards. According to the company, the awards were granted to facilitate these hires and were approved by the compensation committee March 18, 2026.

What Plan governs the BridgeBio (BBIO) inducement awards granted in March 2026?

The awards were granted pursuant to the company’s equity Plan adopted in November 2019 and amended February 10, 2023 and December 13, 2023. According to the company, the grants comply with that Plan and Nasdaq rules.

Do the March 2026 RSU grants for BBIO immediately dilute existing shareholders?

The grants represent 70,916 shares underlying RSUs but vesting is contingent on continued employment. According to the company, these are inducement awards; actual dilution depends on future vesting and settlement of the RSUs under the Plan.